Do We Need to Adjust the Effect-site Concentration of Propofol in Patients Undergoing Chemotherapy?

Overview

Journal Korean J Anesthesiol

Specialty Anesthesiology

Date 2022 Apr 5

PMID 35378573

Authors

Ki Tae Jung

Affiliations

Soon will be listed here.

References

Choi J, Kim D, Cho C, Park S, Son Y . Trends in medical disputes involving anesthesia during July 2009-June 2018: an analysis of the Korean Society of Anesthesiologists database. Korean J Anesthesiol. 2018; 72(2):156-163. PMC: 6458513. DOI: 10.4097/kja.d.18.00198. View

Wu G, Fu G, Zhang L, Zhang Z, Wang X . Effects of neoadjuvant chemotherapy on the depth of total intravenous anesthesia in patients with breast cancer undergoing unilateral modified radical mastectomy: A prospective observational study. Medicine (Baltimore). 2018; 97(51):e13776. PMC: 6319789. DOI: 10.1097/MD.0000000000013776. View

Adachi Y, Satomoto M, Higuchi H, Watanabe K . The determinants of propofol induction time in anesthesia. Korean J Anesthesiol. 2013; 65(2):121-6. PMC: 3766776. DOI: 10.4097/kjae.2013.65.2.121. View

He Z, Hu Y, Fan Z . Median effective effect-site concentration of intravenous anesthetics for loss of consciousness in neoadjuvant chemotherapy patients. Chin Med J (Engl). 2011; 124(4):504-8. View

Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, Tassi R . Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol. 2007; 61(1):105-11. DOI: 10.1007/s00280-007-0454-3. View

Ki S, Cho Y, Choi Y, Lim S, Kim M, Lee J . Effect of chemotherapy on effect-site concentration of propofol for loss of consciousness in patients with colorectal cancer. Korean J Anesthesiol. 2021; 75(2):160-167. PMC: 8980285. DOI: 10.4097/kja.21327. View

Alam A, Rampes S, Patel S, Hana Z, Ma D . Anesthetics or anesthetic techniques and cancer surgical outcomes: a possible link. Korean J Anesthesiol. 2021; 74(3):191-203. PMC: 8175878. DOI: 10.4097/kja.20679. View

Jung K, Won Y, Hong S, Kong H, Lee E . Prediction of Cancer Incidence and Mortality in Korea, 2020. Cancer Res Treat. 2020; 52(2):351-358. PMC: 7176954. DOI: 10.4143/crt.2020.203. View

Przybylowski K, Tyczka J, Szczesny D, Bienert A, Wiczling P, Kut K . Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery. J Pharmacokinet Pharmacodyn. 2015; 42(2):111-22. PMC: 4355445. DOI: 10.1007/s10928-015-9404-6. View

10.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

11.

Sahinovic M, Struys M, Absalom A . Clinical Pharmacokinetics and Pharmacodynamics of Propofol. Clin Pharmacokinet. 2018; 57(12):1539-1558. PMC: 6267518. DOI: 10.1007/s40262-018-0672-3. View

12.

Gao X, Mi Y, Guo N, Luan J, Xu H, Hu Z . The mechanism of propofol in cancer development: An updated review. Asia Pac J Clin Oncol. 2020; 16(2):e3-e11. DOI: 10.1111/ajco.13301. View

13.

Bienert A, Wiczling P, Grzeskowiak E, Cywinski J, Kusza K . Potential pitfalls of propofol target controlled infusion delivery related to its pharmacokinetics and pharmacodynamics. Pharmacol Rep. 2012; 64(4):782-95. DOI: 10.1016/s1734-1140(12)70874-5. View

14.

Taillibert S, Le Rhun E, Chamberlain M . Chemotherapy-Related Neurotoxicity. Curr Neurol Neurosci Rep. 2016; 16(9):81. DOI: 10.1007/s11910-016-0686-x. View